AUA also issues new guidance on treatment of patients with CRPC

Earlier today, the American Urological Association issued new guidance to its members on the management of patients with non-metastatic and metastatic castration-resistant prostate cancer (CRPC).

Here are links to various appropriate materials that interested readers will probably want to review for themselves:

  • A brief summary of the new guidance is available on the OncLive web site and focuses specifically on issues related to the appropriate use and sequencing of newer agents like sipulecel-T, abiraterone acetate, and enzalutamide as well as older agents like antiandrogens and docetaxel.

This new guidance document uses a series of six different “index” types of patient in order to describe the appropriate use of different clinical options, and it does give some very specific proposals regarding the sequencing of the available agents, although the authors acknowledge that these proposals are not yet confirmed by clinical trial data in many cases, and that they may change relatively quickly over time.

One Response

  1. Mike:

    Thank you for posting this and the links. Very helpful.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: